Patents Assigned to Fundação Oswaldo Cruz—FIOCRUZ
-
Patent number: 10617746Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (SM14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic compositions and diagnostic kits using peptide fragments.Type: GrantFiled: April 28, 2017Date of Patent: April 14, 2020Assignee: Fundaçao Oswaldo Cruz—FIOCRUZInventors: Miriam Tendler, Richard Charles Garratt, Naftale Katz, Andrew John George Simpson, Frank Jefferson Alarcon de Barrientos, Mônica Magno Vilar, Marilia Sirianni dos Santos Almeida
-
Patent number: 9932391Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: October 25, 2016Date of Patent: April 3, 2018Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs, Fundaçäo Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 9505809Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: April 20, 2016Date of Patent: November 29, 2016Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 9346858Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: August 5, 2015Date of Patent: May 24, 2016Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 9133250Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: May 19, 2014Date of Patent: September 15, 2015Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 8909483Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (Sm14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic composition and diagnostic kit using peptide fragments of the present invention.Type: GrantFiled: November 1, 2012Date of Patent: December 9, 2014Assignee: Fundação Oswaldo Cruz—FIOCRUZInventors: Miriam Tendler, Richard Charles Garratt, Naftale Katz, Andrew John George Simpson, Frank Jefferson Alarcon de Barrientos, Mônica Magno Vilar, Marilia Sirianni dos Santos Almeida
-
Patent number: 8802835Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: April 24, 2013Date of Patent: August 12, 2014Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America as represented by the Department of Veteran Affairs, Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 8796316Abstract: This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. This invention also refers to a pharmaceutical composition comprising at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to method of treatment or inhibition of tuberculosis and leishmaniasis.Type: GrantFiled: March 15, 2013Date of Patent: August 5, 2014Assignee: Fundacão Oswaldo Cruz—FIOCRUZInventors: Nubia Boechat, Marilia dos Santos Costa, Maria Cristina da Silva Lourenco, Ivan Neves, Jr., Marcelo da Silva Genestra, Vitor Francisco Ferreira
-
Patent number: 8445658Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: June 15, 2012Date of Patent: May 21, 2013Assignees: The United States of America represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FiocruzInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 8436027Abstract: This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. This invention also refers to a pharmaceutical composition comprising at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to methods of treatment or inhibition of tuberculosis and leishmaniasis.Type: GrantFiled: December 29, 2010Date of Patent: May 7, 2013Assignee: Fundacão Oswaldo Cruz—FIOCRUZInventors: Nubia Boechat, Marilia dos Santos Costa, Maria Cristina da Silva Lourenço, Ivan Neves, Jr., Marcelo da Silva Genestra, Vitor Francisco Ferreira
-
Patent number: 8163803Abstract: The present invention relates to lidocaine derived compounds, which present less anesthetic activity than lidocaine itself, but with more anti-inflammatory and spasmolytic activity than said lidocaine as well as pharmaceutical compositions with at least one of these compounds or a salt of those as active principle and to the use of such compositions to treat, prevent or inhibit atopic diseases including asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance. The pharmaceutical composition may be available in spray form, solution, suspension, emulsion destinated to be applied by nebulization, or in any of the pharmaceutical available forms for oral or injectable use.Type: GrantFiled: June 7, 2005Date of Patent: April 24, 2012Assignee: Fundação Oswaldo Cruz—FIOCRUZInventors: Marco Aurélio Martins, Jorge Carlos Santos Da Costa, Núbia Boechat, Rodrigo de Azeredo Siqueira
-
Patent number: 8021673Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: April 1, 2011Date of Patent: September 20, 2011Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvào Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 7935357Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: March 19, 2010Date of Patent: May 3, 2011Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 7718183Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: January 17, 2006Date of Patent: May 18, 2010Assignees: The United States of America represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young